253 related articles for article (PubMed ID: 12805482)
1. Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester.
Nakajima T; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Abe T; Kato J; Sakon K; Naniwa Y; Tanabe H; Niitsu Y
J Pharmacol Exp Ther; 2003 Sep; 306(3):861-9. PubMed ID: 12805482
[TBL] [Abstract][Full Text] [Related]
2. Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide.
Ban N; Takahashi Y; Takayama T; Kura T; Katahira T; Sakamaki S; Niitsu Y
Cancer Res; 1996 Aug; 56(15):3577-82. PubMed ID: 8758929
[TBL] [Abstract][Full Text] [Related]
3. Human renal UOK130 tumor cells: a drug resistant cell line with highly selective over-expression of glutathione S-transferase-pi isozyme.
Wang W; Liu G; Zheng J
Eur J Pharmacol; 2007 Jul; 568(1-3):61-7. PubMed ID: 17509556
[TBL] [Abstract][Full Text] [Related]
4. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
[TBL] [Abstract][Full Text] [Related]
5. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M
Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092
[TBL] [Abstract][Full Text] [Related]
6. Potent isozyme-selective inhibition of human glutathione S-transferase A1-1 by a novel glutathione S-conjugate.
Cacciatore I; Caccuri AM; Cocco A; De Maria F; Di Stefano A; Luisi G; Pinnen F; Ricci G; Sozio P; Turella P
Amino Acids; 2005 Nov; 29(3):255-61. PubMed ID: 16082503
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy of adenovirus mediated CD ::upp/5-FC directed by GSTP1 promoter in cisplatin-resistant ovarian cancer.
Wang Z; Cai L; Wang H
Gynecol Oncol; 2005 Mar; 96(3):643-50. PubMed ID: 15721406
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of glutathione-S-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma.
Seitz G; Bonin M; Fuchs J; Poths S; Ruck P; Warmann SW; Armeanu-Ebinger S
Int J Oncol; 2010 Feb; 36(2):491-500. PubMed ID: 20043085
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationship of ethacrynic acid analogues on glutathione-s-transferase P1-1 activity inhibition.
Zhao G; Yu T; Wang R; Wang X; Jing Y
Bioorg Med Chem; 2005 Jun; 13(12):4056-62. PubMed ID: 15911318
[TBL] [Abstract][Full Text] [Related]
10. Proapoptotic activity of new glutathione S-transferase inhibitors.
Turella P; Cerella C; Filomeni G; Bullo A; De Maria F; Ghibelli L; Ciriolo MR; Cianfriglia M; Mattei M; Federici G; Ricci G; Caccuri AM
Cancer Res; 2005 May; 65(9):3751-61. PubMed ID: 15867371
[TBL] [Abstract][Full Text] [Related]
11. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma.
Pasello M; Michelacci F; Scionti I; Hattinger CM; Zuntini M; Caccuri AM; Scotlandi K; Picci P; Serra M
Cancer Res; 2008 Aug; 68(16):6661-8. PubMed ID: 18701490
[TBL] [Abstract][Full Text] [Related]
12. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
Zhang T; Guan M; Jin HY; Lu Y
Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
[TBL] [Abstract][Full Text] [Related]
13. [Glutathione S transferases-pi].
Takahashi Y; Niitsu Y
Gan To Kagaku Ryoho; 1994 Jun; 21(7):945-51. PubMed ID: 8002632
[TBL] [Abstract][Full Text] [Related]
14. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
15. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program.
Tew KD; Monks A; Barone L; Rosser D; Akerman G; Montali JA; Wheatley JB; Schmidt DE
Mol Pharmacol; 1996 Jul; 50(1):149-59. PubMed ID: 8700107
[TBL] [Abstract][Full Text] [Related]
16. Cellular response to a glutathione S-transferase P1-1 activated prodrug.
Rosario LA; O'Brien ML; Henderson CJ; Wolf CR; Tew KD
Mol Pharmacol; 2000 Jul; 58(1):167-74. PubMed ID: 10860939
[TBL] [Abstract][Full Text] [Related]
17. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
18. Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV).
Katahira T; Takayama T; Miyanishi K; Hayashi T; Ikeda T; Takahashi Y; Takimoto R; Matsunaga T; Kato J; Niitsu Y
Clin Cancer Res; 2004 Dec; 10(23):7934-40. PubMed ID: 15585627
[TBL] [Abstract][Full Text] [Related]
19. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
[TBL] [Abstract][Full Text] [Related]
20. Characterization and resistance mechanisms of cisplatin-resistant human hepatocellular carcinoma cell line.
Yang JX; Luo Y; Qiu HM; Tang WX
Saudi Med J; 2009 Jan; 30(1):35-40. PubMed ID: 19139770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
